Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
March 06, 2025 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other...
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
February 10, 2025 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to...
Retinal Gene Therapy Market Report 2024-2034: Diversification of Targeted Diseases, Combination Therapies, Precision Medicine Approaches, and Gene Editing Driving Opportunities
January 08, 2025 04:03 ET
|
Research and Markets
Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Retinal Gene Therapy Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.Overall world revenue for the Retinal Gene...
Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group
November 25, 2024 10:25 ET
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ...
Ophthalmoscopes Focused Insights 2024-2029 with Baxter, Halma, HEINE Optotechnik, IRIDEX, Rudolf Riester, Nidek, and Zumax Medical Dominating the $86.87 Billion Market
November 05, 2024 07:53 ET
|
Research and Markets
Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmoscopes Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Ophthalmoscopes Market was valued...
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
July 29, 2024 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
July 22, 2024 12:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
June 27, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in...
Global Nonmydriatic Handheld Fundus Cameras Strategic Research Report 2024: Market to Reach $259 Million by 2030 - Glaucoma Prevalence and Need for Screening to Fuel Sales
May 23, 2024 11:08 ET
|
Research and Markets
Dublin, May 23, 2024 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Nonmydriatic...
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
May 21, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support...